PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
A new research perspective was published in Volume 13 of Oncoscience on June 3, 2026, titled "The dual axis of tumorigenesis: ...
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review ...
A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide ...
Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in EGFR-mutant lung cancer models. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results